{"id":"NCT02390219","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease","officialTitle":"A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2015-03-17","resultsPosted":"2017-11-01","lastUpdate":"2017-12-06"},"enrollment":46,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Advanced Lung Disease"],"interventions":[{"type":"DRUG","name":"Lumacaftor","otherNames":["VX-809"]},{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770"]}],"arms":[{"label":"Lumacaftor/Ivacaftor combination","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of LUM/IVA combination therapy in subjects 12 years and older with CF and advanced lung disease and who are homozygous for the F508del CFTR mutation","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 28","effectByArm":[{"arm":"LUM/IVA","deltaMin":43,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["29126871"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":46},"commonTop":["Respiration abnormal","Cough","Dyspnoea","Infective pulmonary exacerbation of cystic fibrosis","Sputum increased"]}}